https://radforsk.no/wp-content/uploads/2019/05/Solberg.jpg632945Elisabeth K. Andersenhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngElisabeth K. Andersen2019-05-07 12:32:002019-05-07 12:42:55Radforsk bevilger 4,5 millioner kroner til kreftforskning
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00Elisabeth K. Andersenhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngElisabeth K. Andersen2018-12-19 08:36:172019-01-17 08:51:41RESOURCES TO PDT/PCI RELATED RESEARCH
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00Elisabeth K. Andersenhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngElisabeth K. Andersen2018-12-18 09:33:492019-01-17 08:51:41Our portfolio company OncoImmunity receives €2.2 million
This acknowledges the potential of Betalutin® to offer therapeutic benefits to patients with follicular lymphoma, says CMO Lisa Rojkjaer in a press release.
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00Elisabeth K. Andersenhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngElisabeth K. Andersen2018-10-25 10:07:592019-01-17 08:51:41Nordic Nanovector receives Promising Innovative Medicine Designation
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00Elisabeth K. Andersenhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngElisabeth K. Andersen2018-10-24 08:46:502019-01-17 08:51:41Om Vaccibody i NRK EKKO
Our portfolio company Targovax reports encouraging disease-free survival (DFS) data from TG01 trial in resected pancreatic cancer: 16.1 months median DFS with TG01 and gemcitabine combination for all 32 patients in the trial 19.5 months DFS in 2nd cohort who received an optimized dosing regimen 94% of patients had mutant RAS specific adaptive immune activation […]
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00Elisabeth K. Andersenhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngElisabeth K. Andersen2018-10-16 08:11:022019-01-17 08:51:41Targovax: Reports full data set on clinical trial of cancer vaccine TG01
Our portfolio company Vaccibody has released an update on the clinical trial of their neoantigen cancer vaccine in phase I/II: 10 patients have been enrolled and vaccination has started. Mads Axelsen, MD, Chief Medical Officer in Vaccibody, said in a press release: “We are very pleased with the enrollment in the neoantigen trial and […]
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00Elisabeth K. Andersenhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngElisabeth K. Andersen2018-10-10 12:36:322019-01-17 08:51:41Vaccibody: First 10 patients enrolled and vaccination started
Our portfolio company Targovax has released interim results from the phase I trial of ONCOS-102 in checkpoint inhibitor refractory melanoma. Dr. Magnus Jäderberg, CMO of Targovax, said in a press release from the company: “Given the limited number of patients who have completed the study to date, it is encouraging to already see a complete […]
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00Elisabeth K. Andersenhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngElisabeth K. Andersen2018-09-30 12:43:192019-01-17 08:51:41Targovax: Encouraging interim results of ONCOS-102
Our portolio company Vaccibody AS just entered a clinical collaboration with U.S. company Nektar Therapeutics. The aim of the collaboration is to evaluate Vaccibody’s personalized cancer neoantigen vaccine, VB10.NEO, in combination with Nektar’s immune treatment NKTR-214, which is a CD-122-biased agonist. In an interview with Norwegian financial paper “Finansavisen”, President and CSO in Vaccibody, […]
http://radforsk.no/wp-content/uploads/2017/09/rf_logo.png00Elisabeth K. Andersenhttp://radforsk.no/wp-content/uploads/2017/09/rf_logo.pngElisabeth K. Andersen2018-09-24 11:49:192019-01-17 08:51:41Vaccibody in collaboration with prestige company Nektar Therapeutics
Radforsk bevilger 4,5 millioner kroner til kreftforskning
/in Radforsk /by Elisabeth K. AndersenSiden oppstarten i 1986 har Radforsk kanalisert 200 millioner kroner av overskuddet tilbake til kreftforskning ved Oslo universitetssykehus.
RESOURCES TO PDT/PCI RELATED RESEARCH
/in Radforsk /by Elisabeth K. AndersenRadforsk will distribute resources to photodynamic therapy and photochemical internalization (PDT/PCI) related research.
Our portfolio company OncoImmunity receives €2.2 million
/in Portfolio Companies /by Elisabeth K. AndersenOncoImmunity receives €2.2 million to roll out its machine-learning platform to enable the development of personalized cancer immunotherapies.
Nordic Nanovector receives Promising Innovative Medicine Designation
/in Portfolio Companies /by Elisabeth K. AndersenThis acknowledges the potential of Betalutin® to offer therapeutic benefits to patients with follicular lymphoma, says CMO Lisa Rojkjaer in a press release.
Om Vaccibody i NRK EKKO
/in Portfolio Companies /by Elisabeth K. AndersenNRK EKKO med innslag om vår porteføljebedrift Vaccibody.
Targovax: Reports full data set on clinical trial of cancer vaccine TG01
/in Portfolio Companies /by Elisabeth K. AndersenOur portfolio company Targovax reports encouraging disease-free survival (DFS) data from TG01 trial in resected pancreatic cancer: 16.1 months median DFS with TG01 and gemcitabine combination for all 32 patients in the trial 19.5 months DFS in 2nd cohort who received an optimized dosing regimen 94% of patients had mutant RAS specific adaptive immune activation […]
Vaccibody: First 10 patients enrolled and vaccination started
/in Radforsk /by Elisabeth K. AndersenOur portfolio company Vaccibody has released an update on the clinical trial of their neoantigen cancer vaccine in phase I/II: 10 patients have been enrolled and vaccination has started. Mads Axelsen, MD, Chief Medical Officer in Vaccibody, said in a press release: “We are very pleased with the enrollment in the neoantigen trial and […]
Targovax: Encouraging interim results of ONCOS-102
/in Radforsk /by Elisabeth K. AndersenOur portfolio company Targovax has released interim results from the phase I trial of ONCOS-102 in checkpoint inhibitor refractory melanoma. Dr. Magnus Jäderberg, CMO of Targovax, said in a press release from the company: “Given the limited number of patients who have completed the study to date, it is encouraging to already see a complete […]
Vaccibody in collaboration with prestige company Nektar Therapeutics
/in Radforsk /by Elisabeth K. AndersenOur portolio company Vaccibody AS just entered a clinical collaboration with U.S. company Nektar Therapeutics. The aim of the collaboration is to evaluate Vaccibody’s personalized cancer neoantigen vaccine, VB10.NEO, in combination with Nektar’s immune treatment NKTR-214, which is a CD-122-biased agonist. In an interview with Norwegian financial paper “Finansavisen”, President and CSO in Vaccibody, […]